米国企業
IONIS PHARMACEUTICALS INC

IONIS PHARMACEUTICALS INCIONS

時価総額

$70.2億

PER

	2010年 12月31日	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Cash and cash equivalents	70	65	124	160	143	129	85	130	279	683	398	869	276	399
Short-term investments	-	-	-	-	-	-	-	-	-	-	-	-	1,710	1,932
Contracts receivable	-	-	-	-	-	-	-	-	13	63	76	62	26	98
Inventories	-	-	-	-	-	-	-	-	9	18	22	25	22	28
Other current assets	7	5	9	8	16	15	15	72	102	140	140	143	168	184
Total current assets	483	360	423	736	837	837	798	1,168	2,208	2,721	2,131	2,345	2,203	2,642
Property, plant and equipment, net	36	97	91	86	89	90	93	122	132	154	181	178	74	71
Right-of-use assets	-	-	-	-	-	-	-	-	-	-	-	-	182	172
Deposits and other assets	-	-	-	-	-	-	-	10	13	28	50	60	75	105
Total assets	550	485	546	847	956	956	912	1,322	2,668	3,233	2,390	2,612	2,534	2,990
Accounts payable	7	8	10	11	18	28	21	25	29	16	17	12	18	26
Accrued compensation	7	9	8	12	12	16	24	25	29	37	66	39	49	68
Accrued liabilities	12	19	15	22	30	28	36	67	48	67	90	89	140	148
Income taxes payable	-	-	-	-	-	-	-	-	-	33	1	0	6	2
Current portion of deferred contract revenue	-	-	-	-	-	-	-	-	160	118	108	98	91	151
0.125 percent convertible senior notes, net	-	-	-	-	-	-	-	-	-	-	293	-	-	44
Other current liabilities	-	-	-	-	-	-	-	-	-	-	-	-	8	9
Current portion of deferred contract revenue	-	-	-	-	-	-	-	-	160	118	108	98	91	151
Total current liabilities	106	76	74	98	115	149	134	225	280	273	583	241	312	448
Other current liabilities	-	-	-	-	-	-	-	-	-	-	-	-	8	9
Total current liabilities	106	76	74	98	115	149	134	225	280	273	583	241	312	448
Long-term deferred contract revenue	-	-	-	-	-	-	-	-	567	490	424	352	288	241
0 percent convertible senior notes due April 2026.	-	-	-	-	-	-	-	-	-	-	-	619	622	625
1.75 percent convertible senior notes due June 2028.	-	-	-	-	-	-	-	-	-	-	-	-	-	562
0.125 percent convertible senior notes due December 2024.	-	-	-	-	-	-	-	-	-	435	456	542	545	-
0 percent convertible senior notes due April 2026.	-	-	-	-	-	-	-	-	-	-	-	619	622	625
0.125 percent convertible senior notes due December 2024.	-	-	-	-	-	-	-	-	-	435	456	542	545	-
Convertible senior notes, net	-	-	144	150	-	-	-	533	568	-	-	-	-	-
Long-term lease liabilities	-	-	-	-	-	-	-	-	-	-	-	-	179	171
Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method.	-	-	-	-	-	-	-	-	-	-	-	-	-	514
Long-term mortgage debt	-	-	-	-	-	-	-	60	60	60	60	60	9	42
Long-term lease liabilities	-	-	-	-	-	-	-	-	-	-	-	-	179	171
Long-term obligations	-	-	-	-	-	-	-	-	-	-	-	-	7	-
Long-term obligations	-	-	-	-	-	-	-	60	60	60	60	60	9	42
Total liabilities	306	313	363	469	698	755	813	903	1,481	1,549	1,546	1,840	1,961	2,603
Common stock, $0.001 par value; 300,000,000 shares authorized, 144,340,526 and 142,057,736 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Additional paid-in capital	1,000	1,014	1,077	1,325	1,225	1,309	1,311	1,550	2,047	2,204	2,114	1,964	2,060	2,215
Accumulated other comprehensive loss	1	-1	12	21	40	-14	-30	-32	-32	-25	-21	-33	-57	-33
Accumulated deficit	-757	-841	-907	-968	-1,007	-1,095	-1,181	-1,187	-967	-708	-1,249	-1,160	-1,430	-1,796
Total stockholders' equity	245	171	183	378	258	201	100	419	1,187	1,685	843	772	573	387
Total liabilities and stockholders' equity	550	485	546	847	956	956	912	1,322	2,668	3,233	2,390	2,612	2,534	2,990